Rep. Morrison Introduces ADINA Act to Require Allergen and Gluten Labels on Medications
The ADINA Act is currently in the early stages of the legislative process and is being reviewed by the House Committee on Energy and Commerce. It is actively moving forward, though no further committee hearings or votes have been scheduled at this time.
Smaller pharmaceutical and supplement manufacturers would need to update their labeling processes to identify and disclose allergen-derived ingredients. While the two-year implementation window gives companies time to adjust, reformulating labels and verifying ingredient sourcing would add compliance costs, especially for companies with many product lines.
Referred to the House Committee on Energy and Commerce.
Sponsor introductory remarks on measure. (CR H2516)
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
The ADINA Act (H.R. 3821) was reintroduced in June 2025 by Rep. Kelly Morrison to mandate labeling for the top 9 food allergens and gluten in medications. Advocacy efforts in early 2026 have seen co-sponsors double as families push for federal transparency on prescription and OTC drug labels.
Profiles Adina Togal, whose hospitalization from an antibiotic with undisclosed allergens inspired the ADINA Act. The bill seeks to close a loophole where pharmaceutical drugs, unlike food products, are not required to list potential allergens like gluten or lactose in their inactive ingredients.
The Allergen Disclosure in Non-Food Articles (ADINA) Act would amend the Food, Drug, and Cosmetic Act to require drug labels to indicate ingredients derived from major food allergens or glutens. Research shows 93% of medicines contain potential allergens, often in undisclosed inactive ingredients.
Document Type
Congressional Bill
Official Title
ADINA Act
Analysis generated by AI. Always verify with official sources.